Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$31.35 Million
AU$50.62 Million AUD
Market Cap Rank
#24655 Global
#511 in Australia
Share Price
AU$0.03
Change (1 day)
+3.33%
52-Week Range
AU$0.02 - AU$0.08
All Time High
AU$0.40
Categories
Companies in Australia Drug Manufacturers - Specialty & Generic
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more

Syntara Ltd - Asset Resilience Ratio

Latest as of June 2005: 85.55%

Syntara Ltd (SNT) has an Asset Resilience Ratio of 85.55% as of June 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$32.45 Million
Cash + Short-term Investments
Total Assets
AU$37.94 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2023)

This chart shows how Syntara Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Syntara Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$32.45 Million 85.55%
Total Liquid Assets AU$32.45 Million 85.55%

Asset Resilience Insights

  • Very High Liquidity: Syntara Ltd maintains exceptional liquid asset reserves at 85.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Syntara Ltd Industry Peers by Asset Resilience Ratio

Compare Syntara Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF 		Drug Manufacturers - Specialty & Generic -0.02%
Kamada
NASDAQ:KMDA 		Drug Manufacturers - Specialty & Generic 21.63%
Dongwha Pharm.Co.Ltd
KO:000020 		Drug Manufacturers - Specialty & Generic 1.92%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 		Drug Manufacturers - Specialty & Generic 0.46%
Yuhan Corp.
KO:000100 		Drug Manufacturers - Specialty & Generic 0.99%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 		Drug Manufacturers - Specialty & Generic 1.81%
Kotra Industries Bhd
KLSE:0002 		Drug Manufacturers - Specialty & Generic 9.82%
Yuyu Pharma Inc
KO:000227 		Drug Manufacturers - Specialty & Generic 1.74%

Annual Asset Resilience Ratio for Syntara Ltd (2005–2023)

The table below shows the annual Asset Resilience Ratio data for Syntara Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-06-30 36.40% AU$8.75 Million AU$24.03 Million +2.67pp
2022-06-30 33.73% AU$8.49 Million AU$25.19 Million -51.82pp
2005-06-30 85.55% AU$32.45 Million AU$37.94 Million --
pp = percentage points